骨髓间充质干细胞衍生的外泌体 miR-206 通过靶向 TRA2B 抑制骨肉瘤进展

核心信息

  • 论文英文标题: Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B
  • 期刊: Cancer Lett
  • 发表年份: 2020
  • DOI: 10.1016/j.canlet.2020.07.008
  • PMID/PMCID: 32682951

研究概览

In this research, we found that overexpression of transformer 2β (TRA2B) was associated with tumor progression in osteosarcoma, and TRA2B was the target gene of miR-206, which was downregulated in osteosarcoma tissues. Taken together, our study demonstrates that BMSC-derived exosomal miR-206 can be transferred into osteosarcoma cells and inhibit tumor progression by targeting TRA2B, which provides new insight into the molecular mechanism of osteosarcoma and highlights the potential of miR-206 and TRA2B as new therapeutic targets.

核心发现

Osteosarcoma is the most common primary malignant bone tumor in young people.

Recently, extracellular vesicles, especially exosomes, have been reported to play an increasingly important role in the development of many types of tumors.

In this research, we found that overexpression of transformer 2β (TRA2B) was associated with tumor progression in osteosarcoma, and TRA2B was the target gene of miR-206, which was downregulated in osteosarcoma tissues.

Furthermore, we observed that bone marrow mesenchymal stem cell (BMSC)-derived exosomes could carry and transport miR-206 to osteosarcoma cells.

Echo Biotech 角色

外泌体分离鉴定

关联平台: Exoomics®

关联服务与能力: EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB)

关联产品或试剂: 无明确产品引用

参考文献

原始论文: Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B Cancer Lett. 2020. DOI: 10.1016/j.canlet.2020.07.008. PMID/PMCID: 32682951.